PriceTargets.com logo

CASI Pharmaceuticals - CASI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 378.09%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.51 As of 04/23/2024 01:00 AM ET
▲ +0.08 (3.29%)

This chart shows the closing price for CASI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CASI Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CASI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CASI

Analyst Price Target is $12.00
▲ +378.09% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CASI Pharmaceuticals in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 378.09% upside from the last price of $2.51.

This chart shows the closing price for CASI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in CASI Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2023HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $12.00Low
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
11/16/2022BTIG ResearchLower TargetBuy$21.00 ➝ $10.00Low
11/15/2022HC WainwrightLower TargetBuy$12.00 ➝ $10.00Low
8/15/2022HC WainwrightBoost TargetBuy$3.00 ➝ $12.00Low
6/3/2022BTIG ResearchBoost TargetBuy ➝ Buy$4.00 ➝ $21.00Low
5/13/2022HC WainwrightLower Target$40.00 ➝ $30.00Low
11/15/2021HC WainwrightReiterated RatingBuy$40.00Medium
5/17/2021BTIG ResearchInitiated CoverageBuy$40.00High
5/14/2021HC WainwrightBoost TargetBuy$35.00 ➝ $40.00Low
4/26/2021MizuhoInitiated CoverageBuy$38.00High
11/10/2020OppenheimerReiterated RatingBuy$50.00High
10/23/2020OppenheimerInitiated CoverageOutperform$50.00High
3/24/2020HC WainwrightReiterated RatingBuy$70.00 ➝ $35.00Medium
5/16/2019HC WainwrightReiterated RatingBuy$70.00Low
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

CASI Pharmaceuticals logo
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Read More

Today's Range

Now: $2.51
Low: $2.36
High: $2.51

50 Day Range

MA: $3.98
Low: $2.24
High: $6.09

52 Week Range

Now: $2.51
Low: $1.85
High: $8.48

Volume

12,047 shs

Average Volume

171,932 shs

Market Capitalization

$33.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CASI Pharmaceuticals?

The following equities research analysts have issued research reports on CASI Pharmaceuticals in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for CASI.

What is the current price target for CASI Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for CASI Pharmaceuticals in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 378.1%. HC Wainwright has the highest price target set, predicting CASI will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for CASI Pharmaceuticals in the next year.
View the latest price targets for CASI.

What is the current consensus analyst rating for CASI Pharmaceuticals?

CASI Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CASI will outperform the market and that investors should add to their positions of CASI Pharmaceuticals.
View the latest ratings for CASI.

What other companies compete with CASI Pharmaceuticals?

Other companies that are similar to CASI Pharmaceuticals include Lexaria Bioscience, Aprea Therapeutics, Theratechnologies, Spruce Biosciences and Viracta Therapeutics. Learn More about companies similar to CASI Pharmaceuticals.

How do I contact CASI Pharmaceuticals' investor relations team?

CASI Pharmaceuticals' physical mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is 861065086063 and its investor relations email address is [email protected]. The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com. Learn More about contacing CASI Pharmaceuticals investor relations.